Invasive aspergillosis in patients with acute myeloid leukemia: difficulties in choosing first-line therapy in real clinical practice and pharmacoeconomic analysis of the feasibility of using new antifungal drugs
Open Access
- 22 May 2025
- journal article
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (2) , 126-137
Abstract
The article discusses the epidemiology and difficulties of diagnosing invasive aspergillosis in patients with acute myeloid leukemia, the role of pharmacokinetic and pharmacogenetic studies in choosing the optimal treatment regimen, and an attempt at pharmacoeconomic analysis to create an optimal treatment strategy for this complication.Keywords
This publication has 42 references indexed in Scilit:
- How do I manage refractory invasive pulmonary aspergillosisClinical Microbiology and Infection, 2024
- EE487 Cost-Effectiveness Analysis of Isavuconazole Versus Liposomal Amphotericin for the Treatment of Invasive Mucormycosis in JordanValue in Health, 2023
- Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates of Aspergillus SpeciesJournal of Medical Mycology, 2022
- Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic‐Pharmacokinetic Prospective Multicenter StudyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2019
- The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United KingdomJournal of Medical Economics, 2019
- High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomesSupportive Care in Cancer, 2019
- Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guidelineClinical Microbiology and Infection, 2018
- Improving the diagnosis of invasive aspergillosis by the detection of Aspergillus in broncho-alveolar lavage fluid: Comparison of non-culture-based assaysJournal of Infection, 2018
- Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysisThe Lancet Infectious Diseases, 2016
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialThe Lancet, 2016